Roche performs “very strongly” in third quarter

Roche has stated its satisfaction with its financial performance during the third quarter of the year.

The firm posted an increase in group sales of 3.1 billion Swiss francs (1.9 billion British pounds) during the period, bringing its total value up to 36.4 billion Swiss francs for the first nine months of the year.

Its pharmaceuticals division has also sustained growth at twice the market average, prompting the firm to raise its outlook expectations for the whole year.

Roche now expects at least high single-digit full-year sales growth with regards to its pharmaceuticals operations.

Chief executive of Roche Severin Schwan commented: “Based on this performance, we expect another very good full-year result. I’m particularly pleased with the excellent progress we’re making in joining forces with Genentech.”

In September, Roche revealed that four members of its corporate executive committee are set to retire and that chief executive of Genentech and existing member of the committee Pascal Soriot would take on the role of chief operating officer.